NEW YORK (Reuters Health) - In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors (ICIs) are more effective and safer than conventional second-line treatment, a new systematic review from The Netherlands reports.
Medical reviewers at the US Food and Drug Administration are an important part of regulating therapeutics and ensuring that patients have access to the right medications, but a recent letter published in BMJ has raised concerns about regulators’ tendency to later transition into industry positions.
Data from the Paris-based Molecular Screening for Cancer Treatment Optimization (MOSCATO) trial demonstrates that establishing molecular portraits improves survival for patients with advanced cancer by tailoring treatment to their genetic makeup. The findings were presented at the Molecular Analysis for Personalised Therapy conference.
When chemotherapy alone is used to treat cancer, some dormant cells may survive and become resistant to additional treatment; but, when combined with immunotherapy, the majority of these cells may be destroyed, according to recent data.
Cancer treatment with the immune checkpoint inhibitors nivolumab and ipilimumab may cause patients to develop inflammatory arthritis or sicca syndrome, claims a study conducted by a group of researchers at Johns Hopkins University in Baltimore, MD.